This company has been marked as potentially delisted and may not be actively trading. NASDAQ:XBIOW Xenetic Biosciences (XBIOW) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Xenetic Biosciences Stock (NASDAQ:XBIOW) 30 days 90 days 365 days Advanced Chart Get Xenetic Biosciences alerts:Sign Up Key Stats Today's Range$17.54▼$17.5450-Day Range$12.01▼$22.9452-Week Range$1.02▼$20.50VolumeN/AAverage Volume800 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewXenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.Read More… Receive XBIOW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIOW Stock News HeadlinesXenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | gurufocus.comXenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business ...May 14, 2025 | gurufocus.comElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly becoming one of the most profitable stories of the year.June 1, 2025 | True Market Insiders (Ad)Xenetic: PeriNess in XBIO-015 study to treat osteosarcoma and Ewing sarcomaMarch 27, 2025 | markets.businessinsider.comXenetic: PeriNess in XBIO-015 study to treat osteosarcoma and Ewing sarcomaMarch 27, 2025 | markets.businessinsider.comXenetic partner PeriNess enters clinical study agreement for XBIO-015March 27, 2025 | markets.businessinsider.comXenetic partner PeriNess enters clinical study agreement for XBIO-015March 27, 2025 | markets.businessinsider.comH.C. Wainwright Remains a Hold on Xenetic Biosciences (XBIO)March 21, 2025 | markets.businessinsider.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XBIOW CIK1534525 Webwww.xeneticbio.com Phone17817787720FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.44 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:XBIOW) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.